Vertex Pharmaceuticals Incorporated
XETRA: VX1.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani
- Employees
- 6,100
- Headquarters
- Boston, United States
- IPO year
- 2007
- Market cap
- €92.5B
- Website
- https://www.vrtx.com
Loading VX1…
Loading profile data…Frequently asked questions about VX1
What does Vertex Pharmaceuticals Incorporated (VX1.DE) do?
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
Where does VX1.DE trade?
Vertex Pharmaceuticals Incorporated (VX1.DE) trades on the Deutsche Börse.
What sector is VX1.DE in?
Vertex Pharmaceuticals Incorporated (VX1.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vertex Pharmaceuticals Incorporated?
Reshma Kewalramani is the chief executive officer of Vertex Pharmaceuticals Incorporated (VX1.DE).
Where is Vertex Pharmaceuticals Incorporated headquartered?
Vertex Pharmaceuticals Incorporated is headquartered in United States.
Does VX1.DE pay a dividend?
Vertex Pharmaceuticals Incorporated (VX1.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VX1.DE go public?
Vertex Pharmaceuticals Incorporated (VX1.DE) completed its initial public offering in 2007.